I think it needs to be understoon that Febridx isn't the core of Lumos. Providing the services to aid in the creation of and the solution to other companies diagnostics efforts also. Febridx is a practical device with understandable metrics to determine someone's illness. The benefit for Lumos is it is also a tangible product investors can work out progress on ie, number of devices sold = revenue.
Febridx - Lateral flow test for diagnosing viral v bacterial infection
Viradx - For diagnosing influenza a+b and covid 19
FFN - Eventually running TLiiQ 2.0 for Hologic foetal testing. Mind you the Burnet Institute also is in the space of meternal and infant testing also. Maybe an agreement could be established for the use of these tests alongside Hologic using the Leelu reader which is the foundation of the new TLiiQ system and the Burnet Institute tests.
Binx IO - In Licence products: Lumos has secured access to and distribution rights for a range of women’s health and sexual health diagnostic products from Binx Health and other point of care diagnostic test providers. These products include cleared, CLIA-waived tests for women’s health, STIs, and other
infectious diseases. In parallel, Lumos has established a team of contract, commission-only sales representatives that routinely call on the outpatient settings where these tests are used. This provides an efficient and cost-effective approach to growing product revenue and developing a sales
channel for our own products. Noting that as of Feb, Binx signed a distribution agreement with Cardinal Health. Lumos did say that there was another major player wanting to distribute febridx. Maybe Cardinal is on the cards?
But on top of these products and licencing arrangements, Lumos is developing tests for Aptatek, Food In Depth and Macropak etc which are tests built around mould testing etc.
12 services agreements. I can only source information on around 5 or so.
Add to My Watchlist
What is My Watchlist?
